270 related articles for article (PubMed ID: 33798008)
21. Identification and prevalence of CD8(+) T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2.
Meij P; Leen A; Rickinson AB; Verkoeijen S; Vervoort MB; Bloemena E; Middeldorp JM
Int J Cancer; 2002 May; 99(1):93-9. PubMed ID: 11948498
[TBL] [Abstract][Full Text] [Related]
22. Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide.
Orentas RJ; Roskopf SJ; Nolan GP; Nishimura MI
Clin Immunol; 2001 Feb; 98(2):220-8. PubMed ID: 11161978
[TBL] [Abstract][Full Text] [Related]
23. Human Leukocyte Antigen (HLA) A*1101-Restricted Epstein-Barr Virus-Specific T-cell Receptor Gene Transfer to Target Nasopharyngeal Carcinoma.
Zheng Y; Parsonage G; Zhuang X; Machado LR; James CH; Salman A; Searle PF; Hui EP; Chan AT; Lee SP
Cancer Immunol Res; 2015 Oct; 3(10):1138-47. PubMed ID: 25711537
[TBL] [Abstract][Full Text] [Related]
24. Induction of EBV latent membrane protein-2A (LMP2A)-specific T cells and construction of individualized TCR-engineered T cells for EBV-associated malignancies.
Zhang C; Tan Q; Li S; Shen L; Zhang J; Liu Y; Yang W; Lu Z
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34210819
[TBL] [Abstract][Full Text] [Related]
25. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
[TBL] [Abstract][Full Text] [Related]
26. Expression of immune-related molecules in primary EBV-positive Chinese nasopharyngeal carcinoma: associated with latent membrane protein 1 (LMP1) expression.
Li J; Zhang XS; Xie D; Deng HX; Gao YF; Chen QY; Huang WL; Masucci MG; Zeng YX
Cancer Biol Ther; 2007 Dec; 6(12):1997-2004. PubMed ID: 18087217
[TBL] [Abstract][Full Text] [Related]
27. Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: a new modality for vaccination.
Ranieri E; Herr W; Gambotto A; Olson W; Rowe D; Robbins PD; Kierstead LS; Watkins SC; Gesualdo L; Storkus WJ
J Virol; 1999 Dec; 73(12):10416-25. PubMed ID: 10559360
[TBL] [Abstract][Full Text] [Related]
28. Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses.
Leen A; Meij P; Redchenko I; Middeldorp J; Bloemena E; Rickinson A; Blake N
J Virol; 2001 Sep; 75(18):8649-59. PubMed ID: 11507210
[TBL] [Abstract][Full Text] [Related]
29. Unbiased Identification of T-Cell Receptors Targeting Immunodominant Peptide-MHC Complexes for T-Cell Receptor Immunotherapy.
Lorenz FKM; Ellinger C; Kieback E; Wilde S; Lietz M; Schendel DJ; Uckert W
Hum Gene Ther; 2017 Dec; 28(12):1158-1168. PubMed ID: 28950731
[TBL] [Abstract][Full Text] [Related]
30. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23.
Wang F; Gregory C; Sample C; Rowe M; Liebowitz D; Murray R; Rickinson A; Kieff E
J Virol; 1990 May; 64(5):2309-18. PubMed ID: 2157887
[TBL] [Abstract][Full Text] [Related]
31. Activated human gammadelta T cells as stimulators of specific CD8+ T-cell responses to subdominant Epstein Barr virus epitopes: potential for immunotherapy of cancer.
Landmeier S; Altvater B; Pscherer S; Juergens H; Varnholt L; Hansmeier A; Bollard CM; Moosmann A; Bisping G; Rossig C
J Immunother; 2009 Apr; 32(3):310-21. PubMed ID: 19242369
[TBL] [Abstract][Full Text] [Related]
32. Detection of Epstein-Barr virus-specific memory CD4+ T cells using a peptide-based cultured enzyme-linked immunospot assay.
Calarota SA; Chiesa A; Zelini P; Comolli G; Minoli L; Baldanti F
Immunology; 2013 Aug; 139(4):533-44. PubMed ID: 23560877
[TBL] [Abstract][Full Text] [Related]
33. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes.
Khanna R; Burrows SR; Nicholls J; Poulsen LM
Eur J Immunol; 1998 Feb; 28(2):451-8. PubMed ID: 9521052
[TBL] [Abstract][Full Text] [Related]
34. 'Off-the-shelf' allogeneic antigen-specific adoptive T-cell therapy for the treatment of multiple EBV-associated malignancies.
Sinha D; Srihari S; Beckett K; Le Texier L; Solomon M; Panikkar A; Ambalathingal GR; Lekieffre L; Crooks P; Rehan S; Neller MA; Smith C; Khanna R
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589524
[TBL] [Abstract][Full Text] [Related]
35. Heterogeneous, restricted patterns of Epstein-Barr virus (EBV) latent gene expression in patients with chronic active EBV infection.
Yoshioka M; Ishiguro N; Ishiko H; Ma X; Kikuta H; Kobayashi K
J Gen Virol; 2001 Oct; 82(Pt 10):2385-2392. PubMed ID: 11562532
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma.
Duraiswamy J; Sherritt M; Thomson S; Tellam J; Cooper L; Connolly G; Bharadwaj M; Khanna R
Blood; 2003 Apr; 101(8):3150-6. PubMed ID: 12468425
[TBL] [Abstract][Full Text] [Related]
37. Genome-Wide Analysis of Epstein-Barr Virus Isolated from Extranodal NK/T-Cell Lymphoma, Nasal Type.
Lin N; Ku W; Song Y; Zhu J; Lu Z
Oncologist; 2019 Sep; 24(9):e905-e913. PubMed ID: 30940744
[TBL] [Abstract][Full Text] [Related]
38. Epstein-Barr virus genetic variation in Vietnamese patients with nasopharyngeal carcinoma: full-length analysis of LMP1.
Nguyen-Van D; Ernberg I; Phan-Thi Phi P; Tran-Thi C; Hu L
Virus Genes; 2008 Oct; 37(2):273-81. PubMed ID: 18663567
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of Epstein-Barr virus latent membrane protein 2 specific T-cell receptors driven by T-cell specific promoters using lentiviral vector.
Yang D; Shao Q; Sun H; Mu X; Gao Y; Jiang R; Hou J; Yao K; Chen Y; Sun B
Clin Dev Immunol; 2011; 2011():716926. PubMed ID: 21969838
[TBL] [Abstract][Full Text] [Related]
40. The generation of LMP2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgkin disease.
Su Z; Peluso MV; Raffegerst SH; Schendel DJ; Roskrow MA
Eur J Immunol; 2001 Mar; 31(3):947-58. PubMed ID: 11241300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
